GE Healthcare Announces First U.S. Markets For New Alzheimer’s Diagnostic Tool For Detection Of Beta Amyloid

PRINCETON, N.J.--(BUSINESS WIRE)--GE Healthcare today announced the first seven markets where Vizamyl™ (Flutemetamol F18 injection), a radioactive diagnostic agent approved by the FDA will be available. Late in the second quarter of 2014, Vizamyl will be available to imaging centers near East Rutherford, NJ, Woburn, MA, Beltsville, MD, East Lansing, MI, Dallas, TX, Phoenix, AZ and Colton, CA. Vizamyl is indicated for PET imaging of the brain to estimate beta amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease or other causes of cognitive decline. Vizamyl is an adjunct to other diagnostic evaluations. The safety and effectiveness of Vizamyl have not been established for predicting the development of dementia or other neurologic conditions or for monitoring responses to therapies. Vizamyl is the only PET imaging tracer for detection of amyloid approved by FDA for visual interpretation of color images.

Help employers find you! Check out all the jobs and post your resume.